Odyssey Health completes Phase I trial for concussion drug PRV-002; drug safe and well-tolerated

Odyssey Health, Inc.

Phase I SAD and MAD trial enrolled 40 healthy volunteers; drug was safe and well-tolerated with no severe adverse events.
Pharmacokinetic analysis showed linear dose-plasma relationship; intranasal route suggests greater brain delivery.
Company plans to proceed to Phase II trials, working with FDA and U.S. military for site identification and study design.
Concussion treatment global market valued at $6.9B (2020), forecast $8.9B by 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.